Physiotherapy in Hematopoietic Stem Cell Transplantation (TRAS)
Effectiveness of Physiotherapy in the Prevention of Physical Sequelae in Patients Treated With Hematopoietic Stem Cell Transplantation. A Pilot Study.
調査の概要
詳細な説明
The main characteristics of the study are:
- Randomized, prospective and longitudinal in patients receiving allogeneic hematopoietic stem cell transplantation clinical trial.
- A descriptive study of skeletal muscle characteristics of patients undergoing allogeneic hematopoietic transplantation for hematologic malignancies before and after carrying out a treatment with stem cells.
- Clinical study of the variables of strength, mobility, proprioception and upper and lower pain in patients with hematologic malignancy member before and after cancer treatment.
- Clinical study of the effectiveness of physiotherapy treatment in clinical characteristics (strength, mobility, proprioception and pain) in patients undergoing allogeneic stem cell transplantation.
- Clinical study of psychosocial variables that are affected by hematological treatment, and the influence on them of a physiotherapy treatment.
The data obtained in this project to identify and treat those functional deficits that appear as a result of cancer treatment and influencing patients, regarding the evolution of the disease and its treatment. They will use different psychosocial questionnaires and functional tests based on scientific evidence and the reliability of these, as well as its specific design for patients with hematologic cancer.
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Murcia、スペイン、30120
- Hospital Clinico Universitario Virgen de la Arrixaca
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients aged between 18 and 70 years.
- Patients with a diagnosis of hematologic malignancy that will be subjected to hematopoietic transplantation.
- Patients offer sufficient guarantee adherence to protocol.
- Patients who have previously signed informed consent.
Exclusion Criteria:
- Patients with inability to walk, before treatment.
- Patients whose medical judgment contraindicated inclusion in a physiotherapy intervention.
- Patients with psychotic traits, brain damage or senility prevention of the correct understanding of physical therapy.
- Patients with inability to sign informed consent or understanding.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Physiotherapy exercises
Strength exercises for the muscles proximal upper limbs and lower limbs and proprioception exercises
|
The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form. The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient. |
|
介入なし:Control group
Patients undergoing allogeneic transplantation without treatment of physiotherapy
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in joint range of motion
時間枠:Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days)
|
Will be evaluated with a universal goniometer following validated protocols of measurement
|
Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days)
|
|
Changes in muscle strength of quadriceps, the gastrocnemius and biceps
時間枠:Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
It is measured with the scale of Daniels and a dynamometer.
|
Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Changes in proprioception
時間枠:Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
It is measured with a balance platform and supports uni and bipodal
|
Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Changes in pain perception
時間枠:Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
It will be evaluated with the visual analogue scale and algometer
|
Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Changes in the perception of fatigue
時間枠:Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
Using the Spanish version of the Brief Fatigue Inventory
|
Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Changes in body mass
時間枠:Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
By using the measurement tool TANITA calculate bone, muscle and fat mass, as well as the amount of fluid of patients at each evaluation.
|
Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Changes in the perception of quality of life
時間枠:Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
Using the self-questionnaire SF-36 health
|
Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Changes in the profile of disease consequences
時間枠:Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
Using the questionnaire Sickness Impact Profile (SIP)
|
Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Changes in coping with the disease
時間枠:Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
Using the scale questionnaire Mental Adjustment to Cancer
|
Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Change in perception of anxiety
時間枠:Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
Using the STAI questionnaire
|
Screening visit (one month before hospital admission); at the time of admission (±3 days); ±2 days before transplantation; after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Hematopoietic recovery
時間枠:After hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
Measuring the rate of graft failure and the transfusion dependence
|
After hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Response to the transplantation
時間枠:After hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
By analyzing the rate and type of response
|
After hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Infectious complications
時間枠:After hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
By measuring the rate, type and severity of infections
|
After hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Noninfectious complications
時間枠:After hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
Measuring the rate of EVOH (number and percentage)
|
After hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Immunological recovery
時間枠:after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
By measuring the number and percentage of B lymphocytes, T lymphocytes and NK lymphocytes.
|
after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Hospitalisations of the patient after transplantation
時間枠:after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
Measuring the number of hospitalizations, the number of days in hospital and the cause of same
|
after hospital discharge (± 3 days); and at 3 and 6 months after transplantation (± 3 days).
|
|
Socio-demographic variables
時間枠:Screening visit (one month before hospital admission)
|
Gender (male, female), academic education (university education, basic education, vocational training), marital status (single, married, divorced, widowed), employment status (self-employed, employed as an employee, unemployed) and distance to hospital (km)
|
Screening visit (one month before hospital admission)
|
|
Clinical variables
時間枠:Screening visit (one month before hospital admission)
|
Medical diagnosis, age (years), height (cm), weight (kg)
|
Screening visit (one month before hospital admission)
|
協力者と研究者
捜査官
- 主任研究者:JORGE MONTSERRAT COLL, MD、Hospital Clinico Universitario Virgen de la Arrixaca
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
幹細胞移植の臨床試験
-
Rutgers, The State University of New Jersey完了
-
Oregon Research Behavioral Intervention Strategies...National Institute on Minority Health and Health Disparities (NIMHD)まだ募集していません黒人中学生のSTEM分野における成功のための学術的支援
-
Sinovac (Dalian) Vaccine Technology Co., Ltd.まだ募集していません
-
Assistance Publique - Hôpitaux de Paris募集
-
Taichung Veterans General Hospital完了心毒性 | 非小細胞肺癌(MeSH用語:Carcinoma, Non-Small-Cell Lung) | 薬物関連の副作用および有害反応(MeSH用語) | EGFRチロシンキナーゼ阻害剤台湾
-
Sun Yat-sen University完了子宮頸癌 | 化学療法効果 | ネオアジュバント療法 | Programmed Cell Death 1 Receptor / アンタゴニストと阻害剤中国
-
National Cancer Institute (NCI)積極的、募集していない低分化型甲状腺がん | 難治性分化型甲状腺がん | 難治性甲状腺癌 | 濾胞性バリアント甲状腺乳頭がん | Tall Cell Variant 甲状腺乳頭がん | 分化型甲状腺がん | 甲状腺濾胞癌 | 甲状腺乳頭癌 | 甲状腺腫瘍細胞癌アメリカ
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ
-
Fondazione del Piemonte per l'Oncologia募集乳がん | 卵巣がん | 結腸直腸がん | 黒色腫 (皮膚がん) | 非小細胞肺癌(MeSH用語:Carcinoma, Non-Small-Cell Lung)イタリア
-
National Cancer Institute (NCI)Exelixis完了再発甲状腺がん | 低分化型甲状腺がん | ステージ I 甲状腺乳頭癌 | II期の甲状腺乳頭癌 | III期の甲状腺乳頭がん | Tall Cell Variant 甲状腺乳頭がん | ステージ I 甲状腺濾胞癌 | II期甲状腺濾胞がん | III期の甲状腺濾胞がん | ステージ IVA 甲状腺濾胞癌 | ステージ IVA 甲状腺乳頭癌 | ステージ IVB 甲状腺濾胞癌 | ステージ IVB 甲状腺乳頭癌 | IVC 期の甲状腺濾胞がん | IVC 期の甲状腺乳頭がん | 甲状腺腫瘍性濾胞癌アメリカ